Jazz Pharmaceuticals plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 35th Annual J.P. Morgan Healthcare Conference 2017
7 slides from Jazz Pharmaceuticals's conference presentation, Jan 9, 2017
Slide 1: Transcript excerpt of J.P. Morgan Healthcare Conference presentation
Exhibit 99.1 Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2017: Bruce Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc … 2016 was a very busy and productive year for Jazz Ph
Slide 2: 35th Annual J.P. Morgan Healthcare Conference, Bruce Cozadd
Relevant slides from Jazz Pharmaceuticals plc’s presentation at the J.P. Morgan Healthcare Conference in San Francisco, California on January 9, 2017: 35th J.P. Bruce © Copyright Morgan Annual CozaddHealthcare 2017 | Chairman Jazz Pharmaceuticals. Conference and CEO JanuaryAll 9, rights 2017reserved
Slide 3: Forward-Looking Statements / Safe Harbor Statement
Forward-Looking “Safe This expected historical and with requirements regulatory applicable development businesses; performance Commission company. from statements, 3results, the slide maintaining those Harbor” new timing regulatory facts. Other deck U.S. approval anticipated. even potential informat
Slide 4: Total Revenues: Expect to meet guidance
Strong TOTAL meet $1,800 $1,485 $1,600 $1,400 $1,200 2014 $0 $200 $400 $600 $800 1$1,000 currently 7year 2014–2015 ended guidance Revenue –REVENUES1Expect 20152016G $1,173 expects InDecember $1,5302 $1,325 millions audited. Growth that, Total 31, for 2016 the revenues year toandended actual include
Slide 5: Xyrem net product sales: Expect to meet guidance
Continued NET In $1,250 $1,000 $779 $750 $500 with 2014 $0 $250 Volume 1(YOY) net FDA 112014 millionsmeet product narcolepsy PRODUCT = and for 20152016G U.S. of EDS Growth 10% $1,100 $955FDA-approved cataplexy the Strong 2015 sales Food intreatment 6%6% patients guidance audited. will –SALES1Expect
Slide 6: Erwinaze/Erwinase net product sales
Focus NET $300 meet $190 $250 $200 treatment $150 $100 hypersensitivity $50 $0 12014 Erwinaze/Erwinase results ALL 122014= PRODUCT guidancemulti-agent –on asparaginase E. may Acute In $215 $203 2015 and regimen with developed coli-derived Building of millions 2015 differ. patients ALL 2016G 2chemoth
Slide 7: Defitelio/defibrotide net product sales
2016 EU: treatment NET $150 age $125 $71 $100 the $75 $50 with $25 $0 12014 Defitelio/defibrotide results EU 132014 treatment =undergoing Indicated VOD PRODUCT following European $71 and pulmonary may U.S. In 2015 and $105 of millions U.S.: with pediatric 2015 differ. Launch severe 2016G of –for $12
Jazz Pharmaceuticals — 35th Annual J.P. Morgan Healthcare Conference 2017 on 6ix